Opendata, web and dolomites

Alpha-Synuclein SIGNED

Blocking the prion-like disease propagation in Parkinson’s disease and related disorders – model development and identification of cell-autonomous and cell non-autonomous factors.

Total Cost €


EC-Contrib. €






 Alpha-Synuclein project word cloud

Explore the words cloud of the Alpha-Synuclein project. It provides you a very rough idea of what is the project "Alpha-Synuclein" about.

neurotoxicity    vitro    cellular    retrogradely    protein    first    transducing    usp19    hypothesized    rostrally    periphery    neurons    forms    initially    preformed    editing    validate    cns    exit    brain    prion    endings    viral    vectors    aggregation    sensory    nervous    brainstem    sciatic    recruit    neuronal    validated    abnormally    once    ubiquitin    muscle    intramuscular    pathogenesis    postmortem    mouse    propagation    blocking    candidate    cas9    tissue    containing    toxicity    transported    synuclein    aggregates    initiated    investigations    makeup    connected    selectively    excretion    genome    tools    a53t    transgenic    central    silence    overexpressing    neurodegeneration    proof    disease    modify    peptidase    cord    cell    spreading    musculus    m83    mechanistic    parkinson    slows    time    behavior    implicated    enter    kinase    misfolded    dysfunction    refine    nerve    hindlimb    oxidative    receiving    seeds    pathogenic    mutant    human    motor    ongoing    crispr    elongation    model    spinal    eef2k    hypothesis    endogenous    genetic    eukaryotic    injecting    prevent    propagate    vivo    genes    stress    raav    activated    alpha    pd    19    femoris    induce   

Project "Alpha-Synuclein" data sheet

The following table provides information about the project.


Organization address
city: AARHUS C
postcode: 8000

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Denmark [DK]
 Total cost 200˙194 €
 EC max contribution 200˙194 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2017
 Funding Scheme MSCA-IF-EF-ST
 Starting year 2019
 Duration (year-month-day) from 2019-09-01   to  2021-08-31


Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    AARHUS UNIVERSITET DK (AARHUS C) coordinator 200˙194.00


 Project objective

A prion-like behavior of α-synuclein (AS) protein has been hypothesized in the pathogenesis of Parkinson disease (PD). According to this hypothesis, pathogenic forms “seeds” of AS propagate from periphery into the neurons of central nervous system (CNS), where they recruit endogenous AS in the first receiving neurons, exit the cell and enter connected neurons. The ongoing AS aggregation and cell-cell propagation is considered to induce oxidative stress, neuronal dysfunction and neuronal loss in CNS. Therefore, blocking the neuronal propagation of AS will prevent AS neurotoxicity and neurodegeneration. I propose to develop and validate a novel in vivo model of prion-like AS propagation, in which I will selectively modify the genetic makeup of first receiving neurons, and use this model for mechanistic investigations. I will use a transgenic M83 mouse model overexpressing mutant A53T human AS in which prion-like spreading is initiated by injecting preformed AS aggregates into the hindlimb musculus femoris. These AS aggregates are taken up by sensory and/or motor nerve endings in the muscle, are retrogradely transported through the sciatic nerve into spinal cord, and rostrally into the brainstem and higher brain areas over time. I will refine this model by transducing the sciatic nerve endings with intramuscular delivery of rAAV viral vectors- containing novel CRISPR/Cas9 genome editing tools targeting genes of interest- to prevent in vivo prion-like AS spreading and/or toxicity. As proof of concept, I will silence AS in the receiving neurons to demonstrate this slows the disease development in the model. Once validated, I will use the model for hypothesis-driven mechanistic investigations of candidate genes, which initially include: 1) ubiquitin specific peptidase 19 (USP19)- since it has been implicated in cellular excretion of misfolded AS in vitro, and 2) eukaryotic elongation factor-2 kinase (eEF2K)- since it is abnormally activated in postmortem PD brain tissue.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ALPHA-SYNUCLEIN" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email ( and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "ALPHA-SYNUCLEIN" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

NaWaTL (2020)

Narrative, Writing, and the Teotihuacan Language: Exploring Language History Through Phylogenetics, Epigraphy and Iconography

Read More  

RegARcis (2020)

Role of the SWI/SNF complex in the Androgen Receptor cistrome regulation

Read More  


Emergency Decision Support System of Offshore Platform Fires

Read More